Updated on 10 September 2013
Bayer’s stroke prevention drug Xarelto is facing a growing number of reports of suspected undesirable side-effects
Singapore: German magazine Der Spiegel, while citing data from the Federal Institute for Drugs and Medical Devices (BfArM), reported that Bayer's stroke prevention drug Xarelto is facing a growing number of reports of suspected undesirable side-effects.
The report highlighted that there were a total of 968 cases of suspected undesirable side-effects related to Xarelto in the first eights months of 2013, including 72 cases of death; as compared to 750 cases of side-effects, including 58 cases of death, for the whole of 2012. The report, however, said that the federal organization pointed out that there was no clear proof of a correlation between the drug and side effects.
Anti-clotting drug Xarelto, which has been jointly developed with Johnson & Johnson, is one of Bayer's most important drugs. It earns annual peak sales of more than $2.63 billion (2 billion euros).